問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Radiation Therapy

Division of Otolaryngology

Division of Hematology & Oncology

更新時間：2024-06-04

楊慕華Yang, Muh-Hwa
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

Recruiting Trial

80Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊慕華

List

132Cases

2020-12-01 - 2021-06-29

Phase II/III

A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Test Drug

    GSK3359609

Participate Sites
7Sites

Recruiting1Sites

Terminated6Sites

2021-11-16 - 2024-02-06

Phase I/II

A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    NM21-1480

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2015-04-01 - 2023-12-31

Phase III

A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
6Sites

Terminated5Sites

楊慕華
Taipei Veterans General Hospital

Division of Hematology & Oncology

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2014-01-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2011-09-01 - 2016-09-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2019-06-01 - 2024-03-29

Phase IV

An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)

  • Condition/Disease

    Solid Tumor

  • Test Drug

    IMFINZI (Durvalumab)

Participate Sites
5Sites

Recruiting5Sites

2017-12-01 - 2018-06-03

Phase III

A Phase 1b/3 Multicenter, Randomized Trial of Talimogene Laherparepvec in combination with Pembrolizumab for theTreatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Condition/Disease

    Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    IMLYGIC

Participate Sites
6Sites

Terminated6Sites

2012-06-01 - 2013-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2008-03-20 - 2011-01-31

Phase III

A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINTM, AZD2171) in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer

  • Condition/Disease

    Colorectal Cancer

  • Test Drug

    AZD2171

Participate Sites
4Sites

Terminated4Sites

2018-07-01 - 2021-12-31

Phase III

A Phase III, Randomized, Placebo Controlled, Multicenter, Double-Blind Study Comparing Toripalimab Injection (JS001) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer

  • Condition/Disease

    Nasopharyngeal Cancer

  • Test Drug

    JS001

Participate Sites
8Sites

Terminated7Sites

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

楊慕華
Taipei Veterans General Hospital

Division of Hematology & Oncology

1 10 11 12 13 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB